Journal of Oncology / 2012 / Article / Tab 1

Clinical Study

Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression

Table 1

Upregulated salivary proteins.

Access no.Gene ID%CovNameRatioP value

P63261ACTG65.1Actin, cytoplasmic 21.2070.030
P07108ACBP28.7Acyl-CoA-binding protein1.1610.002
P06733ENOA61.3Alpha-enolase1.1930.030
P04083ANXA156.1Annexin A11.4570.000
P03973ALK136.4Antileukoproteinase 1 precursor2.1880.004
Q8N4F0BPIL127.3Bactericidal/permeabilityincreasing1.3860.000
P35321SPR1A70.8Cornifin-A1.6960.003
P22528SPR1B61.8Cornifin-B1.7220.000
P01040CYTA87.8Cystatin-A1.7880.000
P04080CYTB72.4Cystatin-B1.5140.000
P01034CYTC62.3Cystatin-C precursor1.1830.030
P35527K1C925.5Cytokeratin-91.5120.001
Q9UGM3DMBT139.0Deleted in malignant brain tumors 11.1910.000
Q01469FABPE45.2Fatty acid-binding protein, epidermal1.1910.000
P01877IGHA252.6Ig alpha-2 chain C region1.1250.040
P01834KAC88.7Ig kappa chain C region1.1280.040
P06309KV20531.6Ig kappa chain V-II region GM6071.2740.030
P18510IL1RA31.6Interleukin-1 receptor antagonist protein2.0500.000
P22079PERL46.5Lactoperoxidase precursor1.1900.000
P31025LCN146.6Lipocalin-1 precursor1.8530.000
P26038MOES15.3Moesin1.9910.020
P62937PPIA58.2Peptidyl-prolyl cis-trans-isomerase A1.5530.003
P01833PIGR58.4Polymeric-immunoglobulin receptor1.4520.000
Q16378PROL458.2Proline-rich protein 4 precursor3.0920.000
P05109S10A858.1Protein S100-A81.3180.000
P06702S10A957.0Protein S100-A91.8330.000
Q96DA0U77327.5Protein UNQ773/PRO1567 precursor1.9300.000
P29508SPB320.3Serpin B32.9100.000
Q96DR5SPLC252.2Short-palate lung and nasal epith. carc.1.4350.000
Q9UBC9SPRR381.1Small proline-rich protein 32.0350.000
P60174TPIS42.2Triosephosphate isomerase1.2570.012
P07477TRY135.2Trypsin-1 precursor3.1350.000
P62988UBIQ68.4Ubiquitin1.1420.003
Q6P5S2CF05831.8Uncharacterized protein C6orf581.6030.000

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.